Earnings results often indicate what direction a company will take in the months ahead. With Q1 behind us, let’s have a look ...

Regeneron Pharmaceuticals has declined to submit a new bid for genetic testing company 23andMe exceeding its original winning ...

Regeneron bids for 23andMe at a discounted price of $256 million. The testing firm was once valued at $3.5 billion.

TTAM will acquire substantially all of 23andMe’s assets for $305 million, including its Personal Genome Service and Research ...

Genetic testing firm 23andMe is set to be acquired by drug company Regeneron Pharmaceuticals following its bankruptcy in March, the companies announced on Monday, May 19. Regeneron purchased the ...

Biotechnology company Regeneron Pharmaceuticals is buying 23andMe for $256 million, two months after the genetic testing company filed for Chapter 11 bankruptcy protection. In March 23andMe said ...

A buyer had actually already been found for 23andme, but a competitor is not giving up: The ex-boss of the company may have secured another auction.

Bankrupt genetic testing company 23andMe has been sold to Regeneron Pharmaceuticals for $256 million. The deal includes ...

Biotechnology company Regeneron Pharmaceuticals is buying 23andMe for $256 million, two months after the genetic testing company filed for Chapter 11 bankruptcy protection.